back to Directory

Deep Genomics

Deep Genomics logo

Founded
2014
Patents
12
Publications
38

Technologies

AI Companies (Drug Discovery) Gene Therapy Startups

Deep Genomics is using artificial intelligence to build a new universe of life-saving genetic therapies.
The future of medicine will rely on artificial intelligence, because biology is too complex for humans to understand. At Deep Genomics, our geneticists, molecular biologists and chemists develop new ways of detecting and treating disease using our biologically accurate artificial intelligence technology.

Interviews


Posts Mentioning This Company

19 Companies Pioneering AI Foundation Models in Pharma and Biotech

  
Foundation models represent a new paradigm in artificial intelligence (AI), revolutionizing how machine learning models are developed and deployed. As these models grow increasingly capable, they become useful for applications across a wide range of economic functions and industries, including biotech. Foundation models are a class of large-scale machine learning …

7 Promising RNA Biotech Companies To Watch in 2024

  
For many years the focus of therapeutic developments and scientific research was directed at the genome and proteins. Yet, there is a completely different level of cell regulation – transcriptome level, presented by Ribonucleic acids (RNAs). RNA molecules are not just intermediates between DNA and proteins, in fact, they also carry …

14 Cutting-Edge Startups Focusing On RNA Research

  
For many years, the focus of therapeutic developments and scientific research was directed at the genome and proteins. Yet, there is a completely different level of cell regulation: the transcriptome level, presented by ribonucleic acids (RNAs).

The Growing Momentum for AI Foundation Models in Biotech and 12 Notable Companies

  
As artificial intelligence (AI) foundation models grow increasingly capable, they become useful for applications across a wide range of economic functions and industries, including biotech. The most prominent examples of general purpose foundation models are the GPT-3 and GPT-4 models, which form the basis of ChatGPT, and BERT, or Bidirectional …

2022 in Retrospect: 10 Breakthrough Technologies in Drug Discovery

  
Reflecting on 2022, let’s review several breakthrough technologies that are shaping the future of biology research and drug discovery. I have prepared this list based on a review of recent articles published on BiopharmaTrend -- by myself and by numerous guest authors.

15 Biopharma Research Trends to Watch in 2022

  
Table of contents:    mRNA vaccines and RNA therapies  Epitranscriptomics Targeting RNA with small molecules Deep learning and big data in drug discovery Neoantigens Theranostics  Exosomes Synthetic Biology 3D Bioprinting Antibiotics “anti-trend” (and hope?) Nanotechnologies in Drug Delivery Gene Editing (CRISPR-Cas9) Aging research  Microbiome  Protein Degraders   Discoveries made in …

Technology Meets Biology in Canada

  
Over the past decade, Canada emerged as a promising global location for drug discovery and biotech business, especially when it comes to applying advanced technologies, such as artificial intelligence (AI) and quantum computing in life sciences.

Toronto’s Blossoming AI-driven Drug Discovery Scene

  
Canada has established itself as a rapidly growing global hub for artificial intelligence (AI) innovation and commercialization. This roots deep into the history of early programs and funding provided by Canadian Institute for Advanced Research (CIFAR) and the Natural Sciences and Engineering Research Council of Canada (NSERC) to such AI …

Insilico Medicine and Other AI Drug Discovery Companies Leading the Race

  
A Hong Kong-based artificial intelligence (AI)-driven drug discovery company Insilico Medicine has just announced the appointment of Dr. Michelle Chen as a Chief Business Officer (CBO) to oversee the company’s corporate strategies and business development activities. Dr. Chen is a lofty hire, having more than 20 years of experience in …

Major VC Rounds For AI-driven Biotechs in 2020

  
The ongoing COVID19 crisis forced biotech-oriented venture capitalists (VC) to somewhat slow down the pace of their usual deal-flow -- according to data by PitchBook biopharma venture deals in 2020 are down roughly 16% compared to last year.  However, there is still a lot going on in drug discovery and …